|Combination antiretroviral therapy and the risk of myocardial infarction|
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
|Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies|
M Egger, M May, G Chŕne, AN Phillips, B Ledergerber, F Dabis, ...
The Lancet 360 (9327), 119-129, 2002
|Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies|
Antiretroviral Therapy Cohort Collaboration
The Lancet 372 (9635), 293-299, 2008
|Changing patterns of mortality across Europe in patients infected with HIV-1|
A Mocroft, S Vella, TL Benfield, A Chiesi, V Miller, P Gargalianos, ...
The Lancet 352 (9142), 1725-1730, 1998
|Decline in the AIDS and death rates in the EuroSIDA study: an observational study|
A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, AA Monforte, ...
The Lancet 362 (9377), 22-29, 2003
|Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study|
S Collins, T Mertenskoetter, E Loeliger, R Tressler, I Weller, N Friis-M°ller, ...
Archives of internal medicine 166 (15), 1632-1641, 2006
|Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study|
N Friis-M°ller, R Weber, P Reiss, R ThiÚbaut, O Kirk, AA Monforte, ...
Aids 17 (8), 1179-1193, 2003
|Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration|
CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, ...
The Lancet 384 (9939), 241-248, 2014
|Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverseá…|
SW Worm, C Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, ...
The Journal of infectious diseases 201 (3), 318-330, 2010
|Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients|
AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ...
Aids 14 (5), 499-507, 2000
|Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature|
A Ammassari, MP Trotta, R Murri, F Castelli, P Narciso, P Noto, J Vecchiet, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S123-S127, 2002
|Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.|
A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, ...
Journal of acquired immune deficiency syndromes (1999) 28 (5), 445-449, 2001
|Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study|
S De Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, ...
Diabetes care 31 (6), 1224-1229, 2008
|Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies|
A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ...
The lancet HIV 4 (8), e349-e356, 2017
|Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing|
E Girardi, CA Sabin, AA Monforte
JAIDS Journal of Acquired Immune Deficiency Syndromes 46, S3-S8, 2007
|Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study|
A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, ...
Aids 16 (12), 1663-1671, 2002
|Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?|
E Fontas, F Van Leth, CA Sabin, N Friis-M°ller, M Rickenbach, ...
The Journal of infectious diseases 189 (6), 1056-1074, 2004
|Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons|
A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, ...
Psychosomatics 45 (5), 394-402, 2004
|Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study|
N Friis-M°ller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ...
European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010
|Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy|
G Marchetti, GM Bellistrý, E Borghi, C Tincati, S Ferramosca, ...
Aids 22 (15), 2035-2038, 2008